{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:29:51Z","timestamp":1786336191525,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360162"],"award-info":[{"award-number":["82360162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Jiangxi Province Thousands of Plans","award":["jxsq2023201105"],"award-info":[{"award-number":["jxsq2023201105"]}]},{"name":"The Hengrui Diabetes Metabolism Research Fund","award":["Z-2017-26-2202-4"],"award-info":[{"award-number":["Z-2017-26-2202-4"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["202201011395"],"award-info":[{"award-number":["202201011395"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The relationship between metabolic dysfunction-associated steatohepatitis (MASH) and ischemic heart disease (IHD) remains incompletely understood. This study investigated this association in the U.S. adults utilizing the FibroScan-AST (FAST) score, a validated non-invasive tool for identifying high-risk MASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included 3,696 adults in the 2017\u20132018 National Health and Nutrition Examination Survey. We defined high-risk MASH as FAST score\u2009\u2265\u20090.35. We performed logistic regression to investigate the association between high-risk MASH and prevalent IHD. FAST was calculated by liver stiffness measurement (LSM), controlled attenuation parameter (CAP), and aspartate aminotransferase (AST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of IHD was significantly higher in the high-risk MASH group than in the non-high-risk group (10.5% vs. 5.8%). Both LSM (adjusted odds ratio (aOR) 1.84, 95% CI 1.28\u20132.65) and CAP (aOR 3.06, 95% CI 1.32\u20137.12) were independently associated with IHD after adjustment, whereas AST did not demonstrate a significant association (aOR 0.83, 95% CI 0.48\u20131.43). High-risk MASH was independently associated with IHD (aOR: 2.08; 95% CI: 1.18\u20133.65). Subgroup analysis suggested a potential sex-specific interaction (P for interaction\u2009=\u20090.035), with a pronounced association in males (aOR: 2.51; 95% CI: 1.32\u20134.75) but was not statistically significant in females (aOR: 0.36, 95% CI 0.07\u20131.27).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High-risk MASH defined by the FAST score is independently associated with prevalent IHD in the U.S. population. Future prospective cohort studies are warranted to validate whether intervation of high-risk MASH improves cardiovascular outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12937-026-01342-6","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:55:06Z","timestamp":1780412106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between high-risk metabolic dysfunction-associated steatohepatitis and ischemic heart disease: a nationally representative study"],"prefix":"10.1186","volume":"25","author":[{"given":"Bin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"6","key":"1342_CR1","doi-asserted-by":"publisher","first-page":"e005375","DOI":"10.1161\/CIRCOUTCOMES.118.005375","volume":"12","author":"AN Nowbar","year":"2019","unstructured":"Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality From Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019;12(6):e005375.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"1342_CR2","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139\u2013596.","journal-title":"Circulation"},{"issue":"6","key":"1342_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.cmet.2024.04.020","volume":"36","author":"W Xie","year":"2024","unstructured":"Xie W, Gan J, Zhou X, Tian H, Pan X, Liu W, et al. Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti. Cell Metab. 2024;36(6):1269\u2013e869.","journal-title":"Cell Metab"},{"issue":"1","key":"1342_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cmet.2024.10.008","volume":"37","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zheng MH, Liu D, Lin Y, Song SJ, Chu ES, et al. A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis. Cell Metab. 2025;37(1):59\u2013e683.","journal-title":"Cell Metab"},{"issue":"10","key":"1342_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364.","journal-title":"Cell"},{"issue":"5","key":"1342_CR6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"issue":"1","key":"1342_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","volume":"17","author":"M Alexander","year":"2019","unstructured":"Tilg H, Adolph TE, Romeo S, Loomba R. The many pathways driving liver inflammation in MASH. Cell Metab. Published online March 23, 2026. https:\/\/doi.org\/10.1016\/j.cmet.2026.02.018.","journal-title":"BMC Med"},{"issue":"5","key":"1342_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/CIRCRESAHA.119.316337","volume":"126","author":"J Cai","year":"2020","unstructured":"Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circ Res. 2020;126(5):679\u2013704.","journal-title":"Circ Res"},{"issue":"9","key":"1342_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691\u2013705.","journal-title":"Gut"},{"issue":"11","key":"1342_CR10","doi-asserted-by":"publisher","first-page":"43143","DOI":"10.31083\/RCM43143","volume":"26","author":"A Caturano","year":"2025","unstructured":"Caturano A, Nilo D, Lorenzo GD, Rocco M, Tagliaferri G, Piacevole A, et al. Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm. Rev Cardiovasc Med. 2025;26(11):43143.","journal-title":"Rev Cardiovasc Med"},{"issue":"7","key":"1342_CR11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, K\u00fctting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921\u201337.","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"1342_CR12","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","volume":"20","author":"JZK Toh","year":"2022","unstructured":"Zhou XD, Lazarus JV, Krittanawong C, et al. Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management. Lancet Gastroenterol Hepatol. 2026;11(6):521\u2013537.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1342_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362\u201373.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"1342_CR14","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168\u201385.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1342_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology. 2018;155(2):443\u2013e5717.","journal-title":"Gastroenterology"},{"issue":"9","key":"1342_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"1342_CR17","unstructured":"National Center for Health Statistics. NHANES 2017\u20132018. 2020. Available from: https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/ContinuousNhanes\/Manuals.aspx?BeginYear=2017. Cited 2022 July 8."},{"issue":"11","key":"1342_CR18","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1007\/s10620-021-07363-x","volume":"67","author":"AC Cardoso","year":"2022","unstructured":"Cardoso AC, Tovo CV, Leite NC, El Bacha IA, Cal\u00e7ado FL, Coral GP, et al. Validation and Performance of FibroScan\u00ae-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2022;67(11):5272\u20139.","journal-title":"Dig Dis Sci"},{"issue":"13","key":"1342_CR19","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/j.cgh.2020.07.063","volume":"18","author":"P Puri","year":"2020","unstructured":"Puri P, Jain S, Fuchs M. Use of FibroScan-AST Score to Stratify High-Risk Nonalcoholic Steatohepatitis in US Veterans. Clin Gastroenterol Hepatol. 2020;18(13):3060\u20131.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"1342_CR20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1136\/gutjnl-2022-328689","volume":"72","author":"F Ravaioli","year":"2023","unstructured":"Ravaioli F, Dajti E, Mantovani A, Newsome PN, Targher G, Colecchia A. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis. Gut. 2023;72(7):1399\u2013409.","journal-title":"Gut"},{"issue":"1","key":"1342_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, et al. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019;17(1):156\u2013e632.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1342_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/oxfordjournals.aje.a009387","volume":"147","author":"MM Bergmann","year":"1998","unstructured":"Bergmann MM, Byers T, Freedman DS, Mokdad A. Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. Am J Epidemiol. 1998;147(10):969\u201377.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"1342_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.amepre.2016.02.023","volume":"51","author":"SS Yoon","year":"2016","unstructured":"Yoon SS, Dillon CF, Illoh K, Carroll M. Trends in the Prevalence of Coronary Heart Disease in the U.S.: National Health and Nutrition Examination Survey, 2001\u20132012. Am J Prev Med. 2016;51(4):437\u201345.","journal-title":"Am J Prev Med"},{"issue":"6","key":"1342_CR24","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356.","journal-title":"J Hepatol"},{"issue":"463","key":"1342_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1198\/016214503000000611","volume":"98","author":"KN Javaras","year":"2003","unstructured":"Javaras KN, Van Dyk DA. Multiple Imputation for Incomplete Data With Semicontinuous Variables. J Am Stat Assoc. 2003;98(463):703\u201315.","journal-title":"J Am Stat Assoc"},{"issue":"12","key":"1342_CR26","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323(12):1175.","journal-title":"JAMA"},{"issue":"11","key":"1342_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903\u201313.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"1342_CR28","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.14309\/ajg.0000000000003274","volume":"120","author":"HH Lee","year":"2025","unstructured":"Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, et al. Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study. Am J Gastroenterol. 2025;120(10):2321\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"1342_CR29","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstr\u00f6m H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375\u201382.","journal-title":"Gut"},{"issue":"4","key":"1342_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327","volume":"44","author":"M Ekstedt","year":"2006","unstructured":"Ekstedt M, Franz\u00e9n LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865\u201373.","journal-title":"Hepatology"},{"key":"1342_CR32","doi-asserted-by":"publisher","unstructured":"Zhou XD, Chen QF, Fan QY, Kim SU, Yip TC, Petta S et al. Cardiovascular-Kidney-Metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD. Hepatology. Published online December 16, 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001645.","DOI":"10.1097\/HEP.0000000000001645"},{"issue":"2","key":"1342_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12072-021-10167-w","volume":"15","author":"JL Jin","year":"2021","unstructured":"Jin JL, Zhang HW, Cao YX, Liu HH, Hua Q, Li YF, et al. Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. Hepatol Int. 2021;15(2):413\u201323.","journal-title":"Hepatol Int"},{"issue":"9","key":"1342_CR34","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/apt.16324","volume":"53","author":"JG Park","year":"2021","unstructured":"Park JG, Jung J, Verma KK, Kang MK, Madamba E, Lopez S, et al. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;53(9):1030\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1342_CR35","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","volume":"79","author":"E Muzurovi\u0107","year":"2022","unstructured":"Muzurovi\u0107 E, Peng CC-H, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022;79(7):1319\u201326.","journal-title":"Hypertension"},{"issue":"1","key":"1342_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12944-024-02027-x","volume":"23","author":"WF Xi","year":"2024","unstructured":"Xi WF, Yang AM. Association between cardiometabolic index and controlled attenuation parameter in U.S. adults with NAFLD: findings from NHANES (2017\u20132020). Lipids Health Dis. 2024;23(1):40.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"1342_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-021-01374-8","volume":"20","author":"J Park","year":"2021","unstructured":"Park J, Kim G, Kim H, Lee J, Lee YB, Jin SM, et al. The association of hepatic steatosis and fibrosis with heart failure and mortality. Cardiovasc Diabetol. 2021;20(1):197.","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"1342_CR38","doi-asserted-by":"publisher","first-page":"e021654","DOI":"10.1161\/JAHA.121.021654","volume":"10","author":"M Fudim","year":"2021","unstructured":"Fudim M, Zhong L, Patel KV, Khera R, Abdelmalek MF, Diehl AM, et al. Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries. J Am Heart Assoc. 2021;10(22):e021654.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"1342_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/MCG.0b013e31822fb3f7","volume":"46","author":"JP Domanski","year":"2012","unstructured":"Domanski JP, Park SJ, Harrison SA. Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter? J Clin Gastroenterol. 2012;46(5):427\u201330.","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"1342_CR40","first-page":"362","volume":"10","author":"G Pemmasani","year":"2020","unstructured":"Pemmasani G, Yandrapalli S, Aronow W. Sex differences in cardiovascular diseases and associated risk factors in non-alcoholic steatohepatitis. Am J Cardiovasc Dis. 2020;10(4):362\u20136.","journal-title":"Am J Cardiovasc Dis"},{"issue":"1","key":"1342_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.31887\/DCNS.2007.9.1\/ammoeller","volume":"9","author":"AM M\u00f6ller-Leimk\u00fchler","year":"2007","unstructured":"M\u00f6ller-Leimk\u00fchler AM. Gender differences in cardiovascular disease and comorbid depression. Dialogues Clin Neurosci. 2007;9(1):71\u201383.","journal-title":"Dialogues Clin Neurosci"},{"issue":"25","key":"1342_CR42","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/j.jacc.2010.01.054","volume":"55","author":"CJ Pepine","year":"2010","unstructured":"Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women\u2019s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55(25):2825\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"1342_CR43","first-page":"60","volume":"84","author":"F Gersh","year":"2024","unstructured":"Gersh F, O\u2019Keefe JH, Elagizi A, Lavie CJ, Laukkanen JA. Estrogen and cardiovascular disease. Prog Cardiovasc Dis. 2024;84:60\u20137.","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"1342_CR44","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019;70(4):1457\u201369.","journal-title":"Hepatology"},{"issue":"6","key":"1342_CR45","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.cmet.2017.04.033","volume":"25","author":"F Mauvais-Jarvis","year":"2017","unstructured":"Mauvais-Jarvis F, Arnold AP, Reue K. A Guide for the Design of Pre-clinical Studies on Sex Differences in Metabolism. Cell Metab. 2017;25(6):1216\u201330.","journal-title":"Cell Metab"},{"issue":"3","key":"1342_CR46","first-page":"1373","volume":"15","author":"V Gagliano","year":"2024","unstructured":"Gagliano V, Gehrig D, Del Giorno R, Gianini J, Gabutti L. A Population-Based Scoring System to Assess the Impact of Individual Risk Factors on Vascular Health. Aging disease. 2024;15(3):1373.","journal-title":"Aging disease"},{"key":"1342_CR47","doi-asserted-by":"publisher","first-page":"1579879","DOI":"10.3389\/fmed.2025.1579879","volume":"12","author":"W Peng","year":"2025","unstructured":"Peng W, Li Z, Fu N. Association between eGDR and MASLD and liver fibrosis: a cross-sectional study based on NHANES 2017\u20132023. Front Med (Lausanne). 2025;12:1579879.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"1342_CR48","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/hep4.1428","volume":"3","author":"C Labenz","year":"2019","unstructured":"Labenz C, Prochaska JH, Huber Y, Nagel M, Straub BK, Wild P, et al. Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. Hepatol Commun. 2019;3(11):1472\u201381.","journal-title":"Hepatol Commun"},{"issue":"7","key":"1342_CR49","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/apt.15660","volume":"51","author":"JB Henson","year":"2020","unstructured":"Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51(7):728\u201336.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1342_CR50","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1053\/j.gastro.2020.02.020","volume":"158","author":"N Gehrke","year":"2020","unstructured":"Gehrke N, Schattenberg JM. Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease? Gastroenterology. 2020;158(7):1929\u201347. e6.","journal-title":"Gastroenterology"},{"key":"1342_CR51","doi-asserted-by":"crossref","unstructured":"Galatou E, Mourelatou E, Hatziantoniou S, Vizirianakis IS. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxid (Basel). 2022;11(6):1060.","DOI":"10.3390\/antiox11061060"},{"key":"1342_CR52","doi-asserted-by":"crossref","unstructured":"van den Hoek AM, \u00d6zsezen S, Caspers MPM, van Koppen A, Hanemaaijer R, Verschuren L. Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis. Int J Mol Sci. 2022;23(15):8229.","DOI":"10.3390\/ijms23158229"},{"issue":"1","key":"1342_CR53","doi-asserted-by":"publisher","first-page":"16364","DOI":"10.1038\/s41598-024-66287-4","volume":"14","author":"X Wu","year":"2024","unstructured":"Wu X, Yuan C, Pan J, Zhou Y, Pan X, Kang J, et al. CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis. Sci Rep. 2024;14(1):16364.","journal-title":"Sci Rep"},{"issue":"11","key":"1342_CR54","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.tips.2024.08.009","volume":"45","author":"NF Brisnovali","year":"2024","unstructured":"Brisnovali NF, Haney C, Goedeke L. Rezdiffra (resmetirom): a THR-\u03b2 agonist for non-alcoholic steatohepatitis. Trends Pharmacol Sci. 2024;45(11):1081\u20132.","journal-title":"Trends Pharmacol Sci"},{"key":"1342_CR55","doi-asserted-by":"crossref","unstructured":"Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83(5):1326-1340.","DOI":"10.1097\/HEP.0000000000001608"},{"issue":"2","key":"1342_CR56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/med4.70014","volume":"3","author":"M Mubeen","year":"2025","unstructured":"Mubeen M, Sakarwala AS, Bijarani AI, Kamal MT. Enhancing heart health: expanding the use of SGLT2 inhibitors in cardiovascular disease. Med Adv. 2025;3(2):122\u20136.","journal-title":"Med Adv"}],"container-title":["Nutrition Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12937-026-01342-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12937-026-01342-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12937-026-01342-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:02:34Z","timestamp":1786334554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12937-026-01342-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1186\/s12937-026-01342-6","relation":{},"ISSN":["1475-2891"],"issn-type":[{"value":"1475-2891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"28 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NHANES is conducted by the Centers for Disease Control and Prevention (CDC) and the National Center for Health Statistics (NCHS). The NCHS Research Ethics Review Committee reviewed and approved the NHANES study protocol. The study protocol was conducted in strict compliance with the Declaration of Helsinki. All NHANES participants provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"85"}}